Gerstmann-Straüssler-Scheinker PRNP P102L-129V mutation
Tóm tắt
Neuropathological and biochemical studies in a case of Gerstmann-Straüssler-Scheinker disease bearing the PRNP P102L-129V mutation showed numerous multicentric PrPres in the cerebral cortex, striatum, thalamus and cerebellum, PrPres globular deposits in the anterior and posterior horns of the spinal cord, and multiple granular PrPres deposits in the grey and white matter of the encephalon and spinal cord. Western blots with antiPrPres antibodies revealed several weak bands ranging from 36 to 66 kDa, weak bands of 29 and 24 kDa, a strong band of about 20 kDa, a low band of molecular weight around 15 kDa and a weaker band of about 7 kDa. Spongiform degeneration was absent. Hyper-phosphorylated 3R and 4R tau occurred in dystrophic neurites surrounding PrPres plaques, neuropil threads and, to a lesser degree, in the form of neurofibrillary tangles. Gel electrophoresis of sarkosyl-insoluble fractions and western blotting with anti-phospho-tau antibodies showed a pattern similar to that seen in Alzheimer disease cases run in parallel. Dystrophic neurites in the vicinity of PrPres plaques were enriched in voltage dependent anion channel thus suggesting abnormal accumulation of mitochondria. These changes were associated with increased oxidative damage in neurons and astrocytes, Finally, increased expression of active stress kinases, that have the capacity to phosphorylate tau in vitro, p38 (p-38-P) and SAPK/ JNK (SAPK/JNK-P) was found in cell processes surrounding PrP plaques. Together, these observations provide evidences of mitochondrial abnormalities, and increased oxidative stress damage and oxidative stress responses in GSS bearing the PRNP P102L-129V mutation.
Từ khóa
Tài liệu tham khảo
Ironside JW, Ghetti B, Head MW, Piccardo P, Will RG, Prion diseases. In: Love S, Louis DN, Ellison DW (eds) Greenfield’s Neuropathology. London: Hodder Harnold, 2008, pp 1197–1274
Aguzzi A, Prion diseases of humans and farm animals: epidemiology, genetics, and pathogenesis, J Neurochem 2006, 97, 1726–1739
Budka H, Head MW, Ironside JW et al., Sporadic Creutzfeldt-Jakob disease. In: Dickson D (ed) Neurodegeneration: The molecular pathology of dementia and movement disorders, ISN Neuropath Press, Basel, 2003, pp 287–297
Ironside JW, Head MW, Biology and neuropathology of prion diseases. In: Duyckaerts C, Litvan I (eds) Handbook of Clinical Neurology vol 39. Edinburgh, London, New York, Oxford, Philadelphia, St Louis, Sydney, Toronto, 2008, pp779–797
Ironside JW, Head MW, Will RG, Variant Creutzfeldt-Jakob disease. In: Dickson D (ed) Neurodegeneration: The molecular pathology of dementia and movement disorders. Basel: ISN Neuropath Press, 2003, pp 310–306
Ricketts MN, Pergami P, Iatrogenic prion disorders. In: Dickson D (ed) Neurodegeneration: The molecular pathology of dementia and movement disorders, ISN Neuropath Press, Basel, 2003, pp 307–309
van der Kamp MW, Daggett V, The consequences of pathogenic mutations to the human prion protein, Protein Eng Des Sel, 2009, 22, 461–468
Solomon IH, Schepker JA, Harris DA, Prion neurotoxicity: insights from prion protein mutants, Curr Issues Mol Biol, 2010, 2, 51–61
Gerstmann J, Straussler E, Scheinker I, Über eine eigenartige hereditär-familiäre Erkrankung des Zentralnervensystems. Zugleich ein Beitrag zur Frage des vozeitigen lokalen Alterns, Zeitscher Neurol Psychiatr, 1936, 154, 736–762
Ghetti B, Dlouhy SR, Giaconne G et al., Gerstmann-Sträussler-Scheinker disease and the Indiana kindred, Brain Pathol, 1995, 5, 61–75
Young K, Clark HB, Piccardo P et al., Gerstmann-Sträussler-Scheinker disease with the PRNP P 102L mutation and valine at codon 129, Brain Res Mol Brain Res, 1997, 44, 147–150
Ghetti B, Bugiani O, Tagliavini F, Piccardo P, Gerstmann-Straüssler-Scheinker disease. In: Dickson DW (ed) Neurodegeneration: the molecular pathology of dementia and movement disorders. ISN Neuropath Press, Basel, 2003, pp 318–325
Kong Q, Surewicz W, Petersen RB et al., Inherited prion diseases. In: Prusiner SB, ed. Prion biology and diseases. New York: Cold Spring Harbor Laboratory Press, 2004, pp 673–776
Ghetti B, Tagliavini F, Masters CL et al., Gerstmann-Sträussler-Scheinker disease. II. Neurofibrillary tangles and plaques with PrP deposits coexist in an affected family, Neurology, 1999, 39, 1453–1461
Guetti B, Tagliavini F, Giaconne G et al., Familial Gerstmann-Sträussler-Scheinker disease with neurofibrillary tangles, Mol Neurobiol, 1994, 8, 41–48
Alzualde A, Indakoetxea B, Ferrer I et al., A novel PRNP Y 218N mutation in Gerstmann-Sträussler-Scheinker disease with neuroifibrillary degeneration, J Neuropathol Exp Neurol, 2010, 69, 789–800
Petersen RB, Siedlak SL, Lee HG et al., Redox metals and oxidative abnormalities in human prion diseases, Acta Neuropathol, 2005, 110: 232–238
Brazier MW, Lewis V, Ciccotosto GD et al., Correlative studies support lipid peroxidation is linked to PrP(res) propagation as early primary pathogenetic event in prion disease, Brain Res Bull, 2006, 68, 346–354
Yun SW, Gerlach M, Riederer P, Klein MA, Oxidative stress in the brain at early preclinical stages of mouse scrapie, Exp Neurol, 2006, 201, 90–98
Freixes M, Rodriguez A, Dalfo E, Ferrer I, Oxidation, glycoxidation, lipoxidation, nitration, and stress in the cerebral cortex in Creutzfeldt-Jakob disesae, Neurobiol Aging, 2006, 27, 1807–1815
Pamplona R, Naudi A, Gavín R et al, Increased oxidation, glycoxidation, and lipoxidation of brain proteins in prion disease, Free Radic Biol Med, 2008, 45, 1159–1166
Cabiscol E, Ros J, Oxidative damage to proteins: Structural modifications and consequences in cell function. In: Dalla-Donne I, Scaloni A, Butterfield A (eds). Redox proteomics. From protein modifications to cellular dysfunction and diseases. John Wiley and Sons, New Jersey, 2006, pp 399–472
van Leeuwen FW, de Kleijn DP, van den Hurk HH et al., Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer’s and Down patients, Science, 1998, 279, 242–247
Fischer DF, De Vos RA, Van Dijk R, et al., Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain, FASEB J, 2003, 17, 2014–2024
Notari S, Capellari S, Langeveld J et al., A refined method for molecular typing reveals that co-occurrence of PrP(Sc) types in Creutzfeldt- Jakob disease is not the rule, Lab Invest, 2007, 87, 1103–1112
Parchi P, Notari S, Weber P et al., Inter-laboratory assessment of PrPSc typing in Creutzfeldt-Jakob disease: a Western blot study within the NeuroPrion Consortium, Brain Pathol, 2009, 19, 384–391
Bianca M, Bianca S, Vecchio I et al., Gerstmann-Sträussler-Scheinker disease with P 102L-V129 mutation: A case with psychiatric manifestations at onset, Am Genet, 2003, 46, 467–469
Webb TE, Poulter M, Beck J et al., Phenotypic heterogeneity and modifications of P 102L inherited prion disease in an international series, Brain, 2008, 131, 2632–2646
Wadsworth JD, Joiner S, Linehan JM et al., Phenotypic heterogeneity in inherited prion disease ((P 102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein, Brain, 2006, 129, 1557–1569
Giovagnoli AR, Di Fede G, Aresi A et al. Atypical frontotemporal dementia as a new clinical phenotype of Gerstmann-Srtaüssler-Scheinker disease with the PRNP P102L mutation. Description of a previously unreported Italian family, J Neurol Sci, 2008, 29, 405–410
Piccardo P, Dlouhy SR, Lievens PM et al., Phenotypic variability of Gerstmann-Sträussler-Scheinker disease is associated with prion protein heterogeneity, J Neuropathol Exp Neurol, 1998, 57, 979–988
Parchi P, Chen SG, Brown P et al., Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P 102L Gerstmann-Straussler-Scheinker disease, Proc Natl Acad Sci U S A, 1998, 95, 8322–8327
Hill AF, Joiner S, Beck JA et al., Distinct glycoform ratios of protease resistant prion protein associated with PRNP point mutations, Brain, 2006, 129, 676–685
Colucci M, Xie Z, Butefisch CM et al., A novel mutation in the prion protein gene associated with distinct pathology, Brain Pathol, 2000, 10, 672
Ishizawa K, Komori T, Shimazu T et al., Hyperphosphorylated tau deposition parallels prion protein burden in a case of Gerstmann-Sträussler-Scheinker syndrome P 102L mutation complicated with dementia, Acta Neuropathol, 2002, 104, 342–350
Giaconne G, Mangieri M, Capobianco R et al., Tauopathy in human and experimental variant Creutzfeldt-Jakob disease, Neurobiol Aging, 2008, 29, 1864–1873
Sikorska B, Liberski PP, Sobow T et al., Ultrastructural study of florid plaques in variant Creutzfeldt-Jakob disease: a comparison with amyloid plaques in kuru, sporadic Creutzfeldt-Jakob disease and Gerstmann-Straüssler-Scheinker disease, Neuropathol Appl Neurobiol, 2009, 35, 46–59
Wang XF, Dong CF, Zhang J et al., Human tau protein forms complex with PrP and some GSS- and fCJD-related PrP mutants possess stronger binding activities with tau in vitro, Mol Cell Biochem, 2008, 310, 49–55
Goedert M, Introduction to the tauopathies. In: Dickson D (ed) Neurodegeneration: The molecular pathology of dementia and movement disorders, ISN Neuropath Press, Basel, 2003, pp 82–85
Santpere G, Puig B, Ferrer I, Low molecular weight species of tau in Alzheimer’s disease are dependent on tau phosphorylation sites but not on delayed post-mortem delay in tissue processing, Neurosci Lett, 2006, 399, 106–110
Atzori C, Ghetti B, Piva R et al., Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol, 2001, 60, 1190–1197
Ferrer I, Blanco R, Carmona M, Puig B, Phosphorylated mitogenactivated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/ calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies, J Neural Transm, 2001, 108, 1397–1415
Ferrer I, Gomez-Isla T, Puig B et al., Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer’s disease and tauopathies, Curr Alzheimer Res, 2005, 2, 3–18
Ferrer I, Stress kinases involved in tau phosphorylation in Alzheimer’s disease, tauopathies and APP transgenic mice, Neurotox Res, 2004, 6, 469–475
de Pril R, Fisher DF, van Leewen FW, Conformational diseases: an umbrella for various neurological disorders with an impaired ubiquitin-proteasome system, Neurobiol Aging, 2006, 27, 515–523
van Tijn P, de Vrij FM, Schuurman KG et al., Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegeneartive disease, J Cell Sci, 2007, 120, 1615–1623
Luse SA, Smith KR (1964) The ultrastructure of senile plaques. Am J Pathol 44: 553–563
Terry RD, Gonatas NK, Weiss M, Ultrastructural studies in Alzheimer’s presenile dementia, Am J Pathol, 1964, 44, 269–297
Hirai K, Aliev G, Nunomura A et al., Mitochondrial abnormalities in Alzheimer’s disease, J Neurosci, 2001, 21, 3017–3023
Pérez-Gracia E, Torrejón-Escribano B, Ferrer I, Dystrophic neurites of senile plaques in Alzheimer’s disease are deficient in cytochrome c oxidase, Acta Neuropathol, 2008, 116, 261–268
Ferrer I, Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer’s disease, J Bioenerg Biomembr, 2009, 41, 425–431
Terni B, Boada J, Portero-Otin M, Pamplona R, Ferrer I, Mitochondrial ATP-synthase in the entorhinal cortex is a target of oxidative stress at stages I/II of Alzheimer’s disease pathology, Brain Pathol, 2010, 20, 222–233
Li Y, Park JS, Deng JH, Bai Y (2006) Cytochrome c oxidase subunit IV is essential for assembly and respiratory function of the enzyme complex. J Bioenerg Biomembr 38: 283–291
Sultana R, Perluigi M, Butterfield DA, Oxidatively modified proteins in Alzheimer’s disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis, Acta Neuropathol, 2009, 118, 131–150
Martínez A, Portero-Otin M, Pamplona R, Ferrer I, Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates, Brain Pathol, 2010, 20, 281–297
Singh N, Singh A, Das D, Mohan ML, Redox control of prion and disease pathogenesis, Antioxid Redox Signal, 2010, 12, 1271–1294
Korolainen MA, Auriola S, Nyman TA, Alafuzoff I, Pirttilä T (2005) Proteomic analysis of glial fibrillary acidic protein in Alzheimer’s disease and aging brain. Neurobiol Dis 20: 858–870.
Pamplona R, Dalfó E, Ayala V et al., Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets, J Biol Chem, 2005, 280, 21522–21530
Muntané G, Dalfó E, Martínez A et al., Glial fibrillary acidic protein is a major target of glycoxidative and lipoxidative damage in Pick’s disease, J Neurochem, 2006, 99, 177–185
Martínez A, Carmona M, Portero-Otin M et al., Type-dependent oxidative damage in frontotemporal lobar degeneration: cortical astrocytes are targets of oxidative damage, J Neuropathol Exp Neurol, 2008, 67, 1122–1136